Want to join the conversation?
$REGN 2Q15 Call: Based on the strong US EYLEA net sales in 2Q15, the company is increasing its full year US EYLEA net sales guidance to be YoverY growth of between 45-50% from the previously provided range of 30-35%. Recently announced a major collaboration with Sanofi in immuno-oncology.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.